The study in which Biodonostia and a thousand Guipuzcoans take part is about to conclude with positive results, and the approval of the EMA is expected in the middle of the month
––
The Curevac vaccine could join this year the immunization plan against the Covid-19. The clinical trial to prove its effectiveness and safety, in which it participates Biodonostia, is already in the final stretch and could receive the approval of the European Medicines Agency (EMA) “In the middle of June”, advances the director of the ins
–
